Long-acting PrEP | Department of Medicine Blog

Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083

Hanscom B, Marzinke MA, Li X, Donnell D, Bies R, Hendrix CW, Wang Z, Acuipil C, Rinehart A, Collins JW, Rooney JF, Soto Torres L,[...]

By afschroeder • November 9, 2025

Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

Chen-Charles J, De Vos L, Vundhla P, Gebengu A, Rousseau E, Bekker LG, Peters R, Mussa A, Morroni C, Toska E, Babalola CM, Klausner J,[...]

By afschroeder • August 30, 2025

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF,[...]

By sjmartinez • November 24, 2024

Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083

Mitchell KM, Boily MC, Hanscom B, Moore M, Todd J, Paz-Bailey G, Wejnert C, Liu A, Donnell DJ, Grinsztejn B, Landovitz RJ, Dimitrov DT. Estimating[...]

By sjmartinez • February 28, 2023